Alternating Hamiltonian cycles in 22-edge-colored multigraphs

A path (cycle) in a $2$-edge-colored multigraph is alternating if no two consecutive edges have the same color. The problem of determining the existence of alternating Hamiltonian paths and cycles in $2$-edge-colored multigraphs is an $\mathcal{NP}$-complete problem and it has been studied by several authors. In Bang-Jensen and Gutin's book "Digraphs: Theory, Algorithms and Applications", it is devoted one chapter to survey the last results on this topic. Most results on the existence of alternating Hamiltonian paths and cycles concern on complete and bipartite complete multigraphs and a few ones on multigraphs with high monochromatic degrees or regular monochromatic subgraphs. In this work, we use a different approach imposing local conditions on the multigraphs and it is worthwhile to notice that the class of multigraphs we deal with is much larger than, and includes, complete multigraphs, and we provide a full characterization of this class. Given a $2$-edge-colored multigraph $G$, we say that $G$ is $2$-$\mathcal{M}$-closed (resp. $2$-$\mathcal{NM}$-closed)} if for every monochromatic (resp. non-monochromatic) $2$-path $P=(x_1, x_2, x_3)$, there exists an edge between $x_1$ and $x_3$. In this work we provide the following characterization: A $2$-$\mathcal{M}$-closed multigraph has an alternating Hamiltonian cycle if and only if it is color-connected and it has an alternating cycle factor. Furthermore, we construct an infinite family of $2$-$\mathcal{NM}$-closed graphs, color-connected, with an alternating cycle factor, and with no alternating Hamiltonian cycle.Comment: 15 pages, 20 figure

Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy.

Ultraviolet (UV) reactivation reactions are rare and can occur in areas of prior sunburn or UV light therapy after the administration of chemotherapy, antibiotics, and other medications. Reactions may occur within days, as described after methotrexate therapy, or may appear months later, as described with ampicillin. Such reactions have been variably termed UV recall, sunburn recall, photo recall, and photodermatitis reactivation, making classification difficult. We report a UV reactivation reaction in a patient with acute lymphocytic leukemia treated with total body irradiation, etoposide, and methotrexate. We propose the terms UV recall and UV enhancement be used in future reports to classify UV reactivation reactions in a scheme analogous to the terminology for cutaneous reactions after radiotherapy

Blockchain-Based Distributed Marketplace

Developments in Blockchain technology have enabled the creation of smart contracts; i.e., self-executing code that is stored and executed on the Blockchain. This has led to the creation of distributed, decentralised applications, along with frameworks for developing and deploying them easily. This paper describes a proof-of-concept system that implements a distributed online marketplace using the Ethereum framework, where buyers and sellers can engage in e-commerce transactions without the need of a large central entity coordinating the process. The performance of the system was measured in terms of cost of use through the concept of ‘gas usage’. It was determined that such costs are significantly less than that of Amazon and eBay for high volume users. The findings generally support the ability to use Ethereum to create a distributed on-chain market, however, there are still areas that require further research and development

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial

Background : By the early 1980s, tuberculosis treatment was shortened from 24 to 6 months, maintaining relapse rates of 1-2%. Subsequent trials attempting shorter durations have failed, with 4-month arms consistently having relapse rates of 15-20%. One trial shortened treatment only among those without baseline cavity on chest x-ray and whose month 2 sputum culture converted to negative. The 4-month arm relapse rate decreased to 7% but was still significantly worse than the 6-month arm (1.6%, P<0.01).  We hypothesize that PET/CT characteristics at baseline, PET/CT changes at one month, and markers of residual bacterial load will identify patients with tuberculosis who can be cured with 4 months (16 weeks) of standard treatment.Methods: This is a prospective, multicenter, randomized, phase 2b, noninferiority clinical trial of pulmonary tuberculosis participants. Those eligible start standard of care treatment. PET/CT scans are done at weeks 0, 4, and 16 or 24. Participants who do not meet early treatment completion criteria (baseline radiologic severity, radiologic response at one month, and GeneXpert-detectable bacilli at four months) are placed in Arm A (24 weeks of standard therapy). Those who meet the early treatment completion criteria are randomized at week 16 to continue treatment to week 24 (Arm B) or complete treatment at week 16 (Arm C). The primary endpoint compares the treatment success rate at 18 months between Arms B and C.Discussion: Multiple biomarkers have been assessed to predict TB treatment outcomes. This study uses PET/CT scans and GeneXpert (Xpert) cycle threshold to risk stratify participants. PET/CT scans are not applicable to global public health but could be used in clinical trials to stratify participants and possibly become a surrogate endpoint. If the Predict TB trial is successful, other immunological biomarkers or transcriptional signatures that correlate with treatment outcome may be identified. TRIAL REGISTRATION: NCT02821832

The Essential Nucleolar Yeast Protein Nop8p Controls the Exosome Function during 60S Ribosomal Subunit Maturation

The yeast nucleolar protein Nop8p has previously been shown to interact with Nip7p and to be required for 60S ribosomal subunit formation. Although depletion of Nop8p in yeast cells leads to premature degradation of rRNAs, the biochemical mechanism responsible for this phenotype is still not known. In this work, we show that the Nop8p amino-terminal region mediates interaction with the 5.8S rRNA, while its carboxyl-terminal portion interacts with Nip7p and can partially complement the growth defect of the conditional mutant strain Δnop8/GAL::NOP8. Interestingly, Nop8p mediates association of Nip7p to pre-ribosomal particles. Nop8p also interacts with the exosome subunit Rrp6p and inhibits the complex activity in vitro, suggesting that the decrease in 60S ribosomal subunit levels detected upon depletion of Nop8p may result from degradation of pre-rRNAs by the exosome. These results strongly indicate that Nop8p may control the exosome function during pre-rRNA processing